The authors describe key challenges facing the clinical trials community and propose solutions to these issues, including the role the Clinical Trials Transformation Initiative can play in addressing these issues. Specifically, the authors reflect on clinical trial globalization and the harmonization of frameworks and requirements across regions; the challenges associated with balancing the desire for external validity, pragmatic trials, and precision medicine; clinical trial transparency; and operational complexity and the expense of clinical trials. By addressing these challenges, future clinical trials will be more feasible, relevant, and credible, and support both the continuing altruistic contributions of patients and the collection of more meaningful data.
MarshallGBlacklockJCameronCet al. Streptomycin treatment of pulmonary tuberculosis: a medical research council investigation. Br Med J1948; 2: 769–782.
2.
BerryDA. The brave new world of clinical cancer research: adaptive biomarker-driven trials integrating clinical practice with clinical research. Mol Oncol2015; 9: 951–959.
3.
BerrySMConnorJTLewisRJ. The platform trial: an efficient strategy for evaluating multiple treatments. JAMA2015; 313: 1619–1620.
International Council for Harmonisation. Technical requirements for pharmaceuticals for human use, http://www.ich.org/home.html (accessed 16 July 2017).
6.
PenkovDTomasiPEichlerIet al. Pediatric medicine development: an overview and comparison of regulatory processes in the European Union and United States. Ther Innov Regul Sci2017; 51: 360–371.
EichlerHGAbadieEBreckenridgeAet al. Bridging the efficacy-effectiveness gap: a regulator’s perspective on addressing variability of drug response. Nat Rev Drug Discov2011; 10: 495–506.
14.
ThorpeKEZwarensteinMOxmanADet al. A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. J Clin Epidemiol2009; 62: 464–475.
15.
SelkerHPOyeKAEichlerHGet al. A proposal for integrated efficacy-to-effectiveness (E2E) clinical trials. Clin Pharmacol Ther2014; 95: 147–153.
16.
MaloneyA. A new paradigm. “Learn—learn more”; dose-exposure-response at the center of drug development and regulatory approval. Clin Pharmacol Ther2017; 102: 942–950.
Innovative Medicines Initiative. Get real: new methods for real world evidence collection and synthesis, http://www.imi-getreal.eu (accessed 16 July 2017).
BertagnollMMKhozinSMurphyMJ. Data-sharing models. N Engl J Med2017; 376: 2305–2306.
25.
EichlerHGBloechl-DaumBBauerPet al. “Threshold-crossing”: a useful way to establish the counterfactual in clinical trials?Clin Pharmacol Ther2016; 100: 699–712.
26.
BurnsNSMillerPW. Learning what we didn’t know: the SPRINT data analysis challenge. N Engl J Med2017; 376: 2205–2207.
